PegBio Co. Ltd.（派格生物医药（苏州）有限公司）is a leading biopharmaceutical company in China, specializing in manufacturing polyethylene glycol (PEG) and development of PEGylation technology leading to PEGylated drugs as putative NEW Molecule Entities (pNMEs). The Company is located at the BioBay Park in Suzhou, a beautiful city in China. Placed in a brand new building, the laboratory is equipped with the state-of-the-art equipment and devices. The Company has developed proprietary PEG synthesis technology and innovative solutions for random and site-specific PEGylation (1st and 2nd generations of PEGylation) of macromolecules.
PegBio currently provides reagent-grade mPEGs to its domestic and international customers in the academic and pharmaceutical fields. The mPEGs provided vary in molecular weights (from a few hundred to 50 KDa), structures (linear, branched, as well as proprietary multiple-armed), and a variety of activation groups such as succinimidyl succinate, succinimidyl carbonate, maleimide, and aldehyde. The Company is now developing pharmaceutical grade PEGs to meet needs of PEGylated biopharmaceuticals.
PegBio also provides PEGylation services by applying the random and site-specific technologies, to its strategic alliance collaborators for chemical modifications of macromolecules such as peptides, proteins, and antibody fragments. Among PegBio proprietary products, PEGylated peptides and antibody fragments for the treatment of type II diabetes and rheumatoid arthritis are being developed, respectively.